Here, we have examined the association of CYP2C19 and CYP2D6 gene variants translated into PGx phenotypes with treatment outcomes of switching or discontinuation, psychiatric emergency department contacts, and suicide attempt/self-harm in patients with depression with incident new-use of (es)citalopram, sertraline, or fluoxetine in children and adolescents (≤18 years), young adults (19–25), and adults (≥26 years). The gene discussed is CYP2D6; the disease is depressive disorder.